Valuation: Oncopeptides AB

Market Cap 661M 67.32M 60.29M 55.46M 50.25M 93.92M 6.39B 95.68M 265M 3.36B 253M 247M 10.6B P/E 2026 *
-3.52x
P/E 2027 * -7.44x
Enterprise Value 715M 72.81M 65.21M 59.98M 54.35M 102M 6.91B 103M 287M 3.64B 273M 267M 11.47B EV / Sales 2026 *
5.55x
EV / Sales 2027 * 2.9x
Free-Float
96.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Oncopeptides AB

1 day-2.22%
1 week-1.01%
1 month-23.47%
3 months+5.75%
6 months+28.30%
Current year-65.18%
1 week 1.62
Extreme 1.619
1.76
1 month 1.62
Extreme 1.619
3.18
Current year 1.26
Extreme 1.255
4.91
1 year 1.26
Extreme 1.255
6.14
3 years 1.1
Extreme 1.1
9.4
5 years 1.1
Extreme 1.1
50.84
10 years 1.1
Extreme 1.1
215
Manager TitleAgeSince
Chief Executive Officer 46 07/08/2023
Director of Finance/CFO 52 13/11/2023
Chief Tech/Sci/R&D Officer 54 01/09/2023
Director TitleAgeSince
Director/Board Member 65 01/01/2012
Director/Board Member 63 01/02/2017
Chairman 79 17/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
3/20/26 A Free

Chief Technology Officer

3,000 0.0008%
3/18/26 A Buy 14,631 0.0038%
3/17/26 A Free

Investor Relations Manager

66 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-2.22%-1.01%-72.26%-76.74% 67.32M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average +0.08%+6.68%+35.59%+167.81% 39.44B
Weighted average by Cap. +0.18%+5.44%+47.97%+176.63%

Financials

2026 *2027 *
Net sales 129M 13.13M 11.76M 10.81M 9.8M 18.32M 1.25B 18.66M 51.77M 656M 49.27M 48.22M 2.07B 252M 25.62M 22.95M 21.11M 19.13M 35.75M 2.43B 36.42M 101M 1.28B 96.16M 94.12M 4.04B
Net income -167M -16.95M -15.18M -13.96M -12.65M -23.65M -1.61B -24.09M -66.85M -847M -63.62M -62.26M -2.67B -62.47M -6.36M -5.69M -5.24M -4.75M -8.87M -604M -9.04M -25.08M -318M -23.86M -23.36M -1B
Net Debt 54M 5.5M 4.92M 4.53M 4.1M 7.67M 522M 7.81M 21.68M 275M 20.63M 20.19M 866M 68M 6.92M 6.2M 5.7M 5.17M 9.66M 657M 9.84M 27.3M 346M 25.98M 25.42M 1.09B
Projected Income Statement - Annual - Oncopeptides AB
Logo Oncopeptides AB
Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
Employees
69
Date Price Change Volume
30/10/26 SEK 1.673 -2.22% 3,172,990
29/10/26 SEK 1.711 +3.07% 5,456,783
28/10/26 SEK 1.660 -.--% 2,392,687
27/10/26 SEK 1.660 -0.60% 2,994,287
26/10/26 SEK 1.670 -1.18% 2,704,963
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Oncopeptides AB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
1.673SEK
Average target price
2.833SEK
Spread / Average Target
+69.36%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Oncopeptides AB
  1. Stock Market
  2. Stocks
  3. ONCO Stock